Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR30.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR37.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR46.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR41.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR36.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR47.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR28.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR29.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR35.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR26.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR17.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR45.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR13.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR48.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR33.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR25.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR49.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR23.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR39.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR32.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR19.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR40.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR44.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR22.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR18.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR42.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR21.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR34.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR43.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR15.htm
EX-31.2 - EX-31.2 - ARIAD PHARMACEUTICALS INCd413091dex312.htm
EX-32.1 - EX-32.1 - ARIAD PHARMACEUTICALS INCd413091dex321.htm
EX-31.1 - EX-31.1 - ARIAD PHARMACEUTICALS INCd413091dex311.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR20.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR27.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR38.htm
10-Q - 10-Q - ARIAD PHARMACEUTICALS INCd413091d10q.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR24.htm
XML - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCR31.htm
v2.4.0.6
Stockholders' Equity and Warrant Liability
9 Months Ended
Sep. 30, 2012
Stockholders' Equity and Warrant Liability
8. Stockholders’ Equity and Warrant Liability

Authorized Common Stock

At September 30, 2012, the Company had 240,000,000 shares of common stock authorized.

 

Financings

On February 25, 2009, the Company sold 14,378,698 shares of its common stock in a registered direct offering to institutional investors, at a purchase price of $1.69 per share, resulting in net proceeds after fees and expenses of $22.8 million. The investors also received warrants to purchase an additional 10,784,024 shares of the Company’s common stock exercisable at a price of $2.15 per share in cash or pursuant to the net exercise provisions of the warrants. The warrants became exercisable on August 25, 2009 and were scheduled to expire if not exercised by February 25, 2012. During the year ended December 31, 2010, 1,220,414 warrants were exercised for proceeds to the Company of $2.6 million. During the year ended December 31, 2011, a total of 3,757,767 warrants were exercised for proceeds to the Company of $8.1 million. In the first quarter of 2012, the remaining 5,805,843 warrants were exercised for proceeds to the Company of $12.5 million. Prior to exercise, the warrant liability was recorded at fair value, with the adjustment to carrying value recognized in earnings. Upon exercise, the sum of the fair value of the exercised warrants and the proceeds received were credited to additional paid-in-capital and totaled $87.0 million in the first quarter of 2012. Upon the exercise of these remaining warrants, the balance of the warrant liability was credited to stockholders’ equity and the liability was eliminated.

On January 11, 2010, the Company filed a shelf registration statement with the U.S. Securities and Exchange Commission (“SEC”) for the issuance of common stock, preferred stock, various series of debt securities and or warrants or rights to purchase any of such securities, either individually or in units, with a total value of up to $125 million, from time to time at prices and on terms to be determined at the time of any such offering. This filing was declared effective on January 21, 2010. As of September 30, 2012, the Company has $65.8 million of securities remaining available under this shelf registration that can be sold before January 21, 2013.

On December 14, 2011, the Company filed a shelf registration statement with the SEC for the issuance of an unspecified amount of common stock, preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in units, from time to time at prices and on terms to be determined at the time of any such offering. This filing was effective upon filing and will remain in effect for up to three years from filing.

On December 20, 2011, the Company sold 24,725,000 shares of its common stock in an underwritten public offering at a purchase price of $10.42 per share. Net proceeds of this offering, after underwriting discounts and commissions and expenses, were $243.1 million.

 

Changes in Stockholders’ Equity

The changes in stockholders’ equity for the nine-month period ended September 30, 2012 were as follows:

 

                  Accumulated               
            Additional     Other               
     Common Stock      Paid-in     Comprehensive      Accumulated        
$ in thousands    Shares      Amount      Capital     Income      Deficit     Total  

Balance, January 1, 2012

     157,608,702       $ 158       $ 776,946      $ —         $ (556,963    $ 220,141   

Issuance of common stock pursuant to warrant exercises

  

 

5,805,843

  

  

 

6

  

  

 

87,039

  

      

 

87,045

  

Issuance of common stock pursuant to ARIAD stock plans

  

 

3,161,125

  

  

 

3

  

  

 

8,199

  

      

 

8,202

  

Stock-based compensation

           12,289             12,289   

Payment of tax withholding obligations related to stock based compensation

           (2,615          (2,615

Net unrealized gains on marketable securities

             20           20   

Net loss

                (160,419     (160,419 
  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Balance, September 30, 2012

     166,575,670       $ 167       $ 881,858      $ 20       $ (717,382    $ 164,663